Aesthetic Surgery Journal Confirms Efficacy And Consumer Acceptance For Absorbable Suture Suspension
IRVINE, Calif., Jan. 29, 2018 /PRNewswire/ -- Sinclair Pharma is pleased to announce an exciting study on Silhouette InstaLift™, a minimally invasive procedure to lift the skin of the mid-face, published in The Aesthetic Surgery Journal (ASJ) assessing the safety, efficacy and satisfaction of absorbable suture suspension.
The 100-patient study that appeared in the December 2017 ASJ demonstrated high patient satisfaction with Silhouette InstaLift for lifting of the mid-face while improving a number of age related changes. Key findings include that 96 percent of survey respondents found Silhouette InstaLift to be a tolerable treatment while 83 percent of respondents found that the treatment improves age related changes.
Study author Julius Few, MD, a plastic surgeon in Chicago and New York City, notes, "Absorbable suture suspension should be considered a workhorse in minimally invasive lifting of ptotic facial skin."
Silhouette InstaLift is the only FDA-cleared facial rejuvenation treatment with a unique dual action that lifts the mid-face and then adds volume over time for a naturally lifted look. The minimally-invasive procedure uses resorbable suspension sutures with bi-directional cones to redefine the contours of the face. The sutures lift and reposition subdermal tissue while the bi-directional cones hold the suture and facial skin in an elevated position. The suture and cone material are both made of glycolide / L-lactide (PLGA) and over time they stimulate fibroblasts for gradual collagen maturation and are designed to reposition volume in the mid-face for a natural-looking lasting result. It is an ideal solution for men and women who are interested in refreshing their appearance without undergoing major surgery, injections or lasers.
"ASJ brings the latest in clinical advances to our readers," shares plastic surgeon Foad Nahai, MD, FACS, Editor in Chief, Aesthetic Surgery Journal. "At a time when more and more patients are seeking less invasive treatments, the publication of Dr. Few's work is timely and offers plastic surgeons a minimally invasive option for those seeking facial rejuvenation."
Doug Abel, President of Sinclair Pharma US states, "We are delighted with the results of this study that confirms our experience with usage of Silhouette InstaLift to address an unmet need in aesthetics. We know from our physician partners that consumer satisfaction continues to be high, which accounts for why over 1,000 physicians in the US market have sought training and are interested in adding this procedure to their armamentarium."
The treatment takes approximately 45-minutes under local anesthesia, and unlike traditional facelifts there is minimal downtime. Results are visible immediately and improve over time, with lasting lifting effects and collagen regeneration. Silhouette InstaLift is only available from medical professionals.
Access the ASJ abstract here: ASJJULIUSFEWSTUDY
About Silhouette InstaLift
Silhouette InstaLift is a minimally-invasive, resorbable suspension suture with bi- directional cones. The sutures lift and reposition subdermal tissue while the bi- directional cones hold the suture and facial skin in an elevated position. The suture and cone material are both made of glycolide / L-lactide (PLGA) and over time they stimulate fibroblasts for gradual collagen maturation and are designed to reposition volume in the mid-face with a goal of a natural-looking result.
About Sinclair Pharma plc – www.sinclairpharma.com
Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors including ThermiGen in the US.
Thermi®, an Almirall Company, is a leading global manufacturer of temperature controlled radiofrequency technology. The company's flagship product is ThermiRF®, a platform technology that uses temperature as an endpoint for various minimally and non-invasive applications (ThermiTight®, ThermiRase®, ThermiSmooth® Face, ThermiVa®). Thermi also offers the Thermi250TMdevice as the newest innovative RF for body and is the distributor for Silhouette InstaLift (lifting to redefine mid-facial contours).
For more information, visit www.instalift.com
SOURCE Sinclair Pharma
Upcoming Life Sciences Events
- February 2019
- Zurich: 12th Annual European Life Sciences CEO Forum
- March 2019
- Tokyo: BIO Asia International Conference
- Singapore: Phar-East 2019